TL;DR
Researchers have developed a novel fluorescent probe, Rhobo6, that can visualize the extracellular matrix (ECM) in live tissues and organisms. This cell-impermeable dye binds to glycans, which are abundant in the ECM, and becomes fluorescent upon binding, allowing for non-perturbative, wash-free imaging with minimal photobleaching. This breakthrough simplifies ECM visualization, opening new avenues for studying extracellular biology.
What Problem Does This Paper Address?
The extracellular matrix (ECM) is a complex network of molecules crucial for cell signaling, tissue structure, and development. Understanding its spatial organization is vital for many biological processes, including development, wound healing, and disease progression like cancer. However, visualizing the ECM in live systems has been a significant challenge. Existing methods often struggle with poor diffusion of labeling agents, perturbation of ECM structure, limited multiplexing capabilities, and photobleaching. Specifically, labeling individual ECM components is difficult, and collectively labeling the entire ECM without disrupting its native state has remained elusive.
Methods
The core innovation is a new small-molecule fluorophore, Rhobo6. It's designed to be cell-impermeable, preventing it from entering cells and labeling intracellular components, thus ensuring it specifically targets the ECM. Rhobo6 works by binding to glycans, which are widespread on ECM molecules. This binding is reversible and low-affinity, minimizing disruption to the ECM. Crucially, upon binding to glycans (which contain diols), Rhobo6 undergoes a fluorescence turn-on and spectral red-shift. This "turn-on" mechanism provides a strong signal, while the red-shift helps differentiate bound from unbound dye.
Key techniques employed include:
- Synthesis and photophysical characterization: Detailed analysis of Rhobo6's absorption, emission, quantum yield, and contrast upon diol binding.
- In vitro validation: Testing Rhobo6 on purified ECM components (collagen, fibronectin, laminin, aggrecan, hyaluronan) and glycan arrays to assess specificity and binding.
- Cell-based assays: Evaluating cell impermeability and surface labeling on cultured cells, including those engineered to overexpress mucins.
- Ex vivo tissue imaging: Applying Rhobo6 to excised tissues like salivary glands and pancreatic tissue to demonstrate ECM visualization in complex biological samples.
- In vivo imaging: Administering Rhobo6 via injection into mice to assess its distribution and ECM labeling in various organs.
- Live imaging microscopy: Utilizing confocal, two-photon, and STED microscopy to visualize ECM dynamics and structure in live samples.
- FLIM (Fluorescence Lifetime Imaging Microscopy): Used to differentiate between bound and unbound Rhobo6 based on fluorescence lifetime.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- Glycan-rich ECM is a prime target: The ubiquity of glycans across ECM components makes them an excellent target for a broad-spectrum ECM labeling strategy.
- Cell impermeability is key for ECM specificity: By designing Rhobo6 to be cell-impermeable, the authors ensured it remained in the extracellular space, avoiding intracellular labeling and improving signal-to-background ratios.
- "Turn-on" and red-shift fluorescence is a powerful readout: This dual property allows for sensitive detection of ECM binding and can be leveraged for spectral multiplexing.
- Low-affinity binding is advantageous: Reversible, low-affinity binding minimizes perturbation of the ECM, crucial for studying its dynamic roles in biological processes. It also contributes to reduced photobleaching.
- Rhobo6 is a versatile tool: The dye demonstrates efficacy across a wide range of applications, from purified ECM components and cell cultures to excised tissues and live animals, including non-mammalian models.
Key Results
- Broad glycan binding: Rhobo6 showed significant binding to 98 out of 100 glycans on a commercial array, indicating broad specificity.
- ECM component labeling: Rhobo6 successfully labeled purified ECM components like collagen I, fibronectin, laminin, aggrecan, and hyaluronan in vitro.
- Cell-impermeable and ECM-specific: Rhobo6 showed minimal intracellular accumulation in cultured cells, unlike its parent compound Rhobo, and effectively labeled cell-surface glycans.
- Wash-free, non-perturbative imaging: Rhobo6 enabled live imaging of ECM in excised tissues (salivary glands, pancreas) and in vivo in mice, demonstrating rapid diffusion and broad tissue distribution without apparent toxicity.
- Minimal photobleaching: Imaging over 9 hours showed no significant loss of fluorescence, enabling long-term dynamic studies.
- ECM remodeling visualization: Rhobo6 successfully visualized ECM changes in a breast cancer spheroid invasion assay and in MMTV-PyMT mouse models of breast cancer.
- Compatibility with advanced microscopy: Rhobo6 is compatible with STED microscopy for super-resolution imaging of the ECM.
Limitations and Future Work
- Lack of molecular specificity: Rhobo6 labels the ECM broadly and does not distinguish between specific ECM components. For molecularly specific hypotheses, it serves as a starting point, requiring follow-up with more targeted probes.
- Cellular glycocalyx labeling: Rhobo6 is less suitable for labeling the cell-surface glycocalyx compared to methods like metabolic labeling, as it can be dimly labeled and serum can interfere.
- Future directions: The authors suggest opportunities for developing more glycan-selective phenylboronic-acid-modified fluorophores, enhancing oxidative stability, and tuning spectral properties. Further characterization of Rhobo6's mechanism and exploring its use in advanced imaging modalities like PAINT microscopy are also proposed. Potential applications in diagnostic imaging and fluorescence-guided surgery are envisioned, requiring pharmacokinetic characterization.
Summary updated